Zobrazeno 1 - 10
of 152
pro vyhledávání: '"William E, Hellenbrand"'
Autor:
Thomas M. Zellers, Jonathan J. Rome, John P. Cheatham, Jacqueline Kreutzer, John W. Moore, Thomas K. Jones, Lisa Bergersen, Allison K. Cabalka, Daniel R. Turner, Aimee K. Armstrong, William E. Hellenbrand, Danyal Khan, Julie A. Vincent, Robert G. Gray, Shicheng Weng, David T. Balzer, Jeffrey D. Zampi, Alexander J. Javois, Doff B. McElhinney
Publikováno v:
Catheterization and Cardiovascular Interventions. 98
Objective We compared 5-year outcomes of transcatheter pulmonary valve (TPV) replacement with the Melody TPV in the post-approval study (PAS) and the investigational device exemption (IDE) trial. Background As a condition of approval of the Melody TP
Autor:
Thomas K. Jones, Doff B. McElhinney, Julie A. Vincent, William E. Hellenbrand, John P. Cheatham, Darren P. Berman, Evan M. Zahn, Danyal M. Khan, John F. Rhodes, Shicheng Weng, Lisa J. Bergersen
Publikováno v:
Circulation. Cardiovascular Interventions
Supplemental Digital Content is available in the text.
Background: The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preservi
Background: The Melody valve was developed to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves, while preservi
Autor:
Mary Hunt Martin, Jeremy D. Asnes, Shabana Shahanavaz, David T. Balzer, Michelle Riley, Doff B. McElhinney, William E. Hellenbrand, Lynn F. Peng, Robert G. Gray
Publikováno v:
Catheterization and Cardiovascular Interventions. 91:485-494
BACKGROUND Since FDA approval of the Melody valve, transcatheter pulmonary valve replacement (TPVR) has been offered to an expanding population. Limited data exist regarding the safety and feasibility of TPVR in smaller patients. METHODS All patients
Autor:
Constance G. Weismann, Veronika Shabanova, Mohsen Karimi, Jeremy D. Asnes, Wendy F. Li, Heidi Pollard, William E. Hellenbrand
Publikováno v:
Congenital Heart Disease. 13:140-146
Trans-catheter (TC) pulmonary valve replacement (PVR) has become common practice for patients with right ventricular outflow tract obstruction (RVOTO) and/or pulmonic insufficiency (PI). Our aim was to compare PVR and right ventricular (RV) function
Autor:
Evan M. Zahn, Tal Geva, Matthew J. Gillespie, Lee N. Benson, John P. Cheatham, John E. Mayer, Kan N Hor, Andrew J. Powell, Thomas K. Jones, Mark Osten, Brian T. McHenry, Sharon L. Cheatham, Peter Ewert, Lisa Bergersen, Andreas Eicken, William E. Hellenbrand, Eric Horlick, Andrew M. Crean, Emile A. Bacha
Publikováno v:
The American Journal of Cardiology. 120:1387-1392
This early feasibility study was designed to obtain in vivo data to confirm assumptions on device loading conditions of the Medtronic Harmony transcatheter pulmonary valve (TPV). Secondary objectives included procedural feasibility, safety, and valve
Autor:
Doff B. McElhinney, Aimee K. Armstrong, Felix Berger, John P. Cheatham, Allison K. Cabalka, Lisa Bergersen, Evan M. Zahn, Jacqueline Kreutzer, Andreas Eicken, William E. Hellenbrand, Robert G. Gray
Publikováno v:
JACC: Cardiovascular Interventions. 10:1746-1759
Objectives This study sought to evaluate the incidence of and risk factors for conduit and stent-related outcomes following transcatheter pulmonary valve replacement (TPVR). Background Stent fracture (SF) and right ventricular outflow tract (RVOT) re
Autor:
Ziyad M. Hijazi, Sharon L. Cheatham, Damien Kenny, William E. Hellenbrand, Thomas K. Jones, Kimberly Ray, John P. Cheatham, Carlos A. C. Pedra
Publikováno v:
Journal of Structural Heart Disease. 2:234-240
Autor:
Jonathan J. Rome, Daniel Tanase, Jochen Grohmann, Matthew A. Crystal, Matthew J. Gillespie, Athar M. Qureshi, Shabana Shahanavaz, Larry A. Latson, Jon Love, Doff B. McElhinney, Marc Gewillig, William E. Hellenbrand, Jeremy D. Asnes, David T. Balzer, Brian H. Morray, Farhouch Berdjis
Publikováno v:
Circulation. Cardiovascular interventions. 11(8)
Background: Percutaneous transcatheter pulmonary valve replacement (TPVR) has good clinical and hemodynamic outcomes in treating dysfunctional bioprosthetic valves (BPV) in the pulmonary position. Valve-in-valve therapy can further decrease the inner
Autor:
John F. Rhodes, Thomas K. Jones, Matthew J. Gillespie, Peter Ewert, William E. Hellenbrand, Howaida El-Said, Jacqueline Kreutzer, Doff B. McElhinney, Lars Søndergaard
Publikováno v:
The Annals of Thoracic Surgery. 100:996-1003
Right ventricular outflow tract (RVOT) conduit dysfunction is a limitation of the Ross procedure. Transcatheter pulmonary valve replacement (TPVR) could alter the impact of conduit dysfunction and the risk-benefit balance for the Ross procedure.Retro
Autor:
Jeremy D. Asnes, Evan M. Zahn, Bryan H. Goldstein, Daniel S. Levi, Jeffrey D. Zampi, Martin L. Bocks, Jamil Aboulhosn, Sanjay Sinha, William E. Hellenbrand, Morris Salem
Publikováno v:
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac AngiographyInterventions. 93(3)
Objectives To describe a multi-center experience of percutaneous transcatheter pulmonary valve replacement (TPVR) using the Edwards Sapien S3 Valve. Background Off-label use of the Sapien S3 valve can allow for TPVR in patients with congenital heart